Engineering Macrophages for Cancer Immunotherapy and Drug Delivery.,Advanced Materials

当前位置： X-MOL 学术 › Adv. Mater. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Engineering Macrophages for Cancer Immunotherapy and Drug Delivery.
Advanced Materials ( IF 27.4 ) Pub Date : 2020-08-28 , DOI: 10.1002/adma.202002054
Yuqiong Xia ₁ , Lang Rao ₂ , Huimin Yao ₁ , Zhongliang Wang ₁ , Pengbo Ning ₁ , Xiaoyuan Chen ₂

Affiliation

Macrophages play an important role in cancer development and metastasis. Proinflammatory M1 macrophages can phagocytose tumor cells, while anti‐inflammatory M2 macrophages such as tumor‐associated macrophages (TAMs) promote tumor growth and invasion. Modulating the tumor immune microenvironment through engineering macrophages is efficacious in tumor therapy. M1 macrophages target cancerous cells and, therefore, can be used as drug carriers for tumor therapy. Herein, the strategies to engineer macrophages for cancer immunotherapy, such as inhibition of macrophage recruitment, depletion of TAMs, reprograming of TAMs, and blocking of the CD47‐SIRPα pathway, are discussed. Further, the recent advances in drug delivery using M1 macrophages, macrophage‐derived exosomes, and macrophage‐membrane‐coated nanoparticles are elaborated. Overall, there is still significant room for development in macrophage‐mediated immune modulation and macrophage‐mediated drug delivery, which will further enhance current tumor therapies against various malignant solid tumors, including drug‐resistant tumors and metastatic tumors.

中文翻译：

工程巨噬细胞用于癌症免疫治疗和药物输送。

巨噬细胞在癌症的发展和转移中起着重要的作用。促炎性M1巨噬细胞可以吞噬肿瘤细胞，而抗炎性M2巨噬细胞（如肿瘤相关巨噬细胞（TAM））则促进肿瘤的生长和侵袭。通过工程巨噬细胞调节肿瘤免疫微环境在肿瘤治疗中是有效的。M1巨噬细胞靶向癌细胞，因此可用作肿瘤治疗的药物载体。本文讨论了工程化巨噬细胞以进行癌症免疫治疗的策略，例如抑制巨噬细胞募集，TAM耗竭，TAM重编程以及CD47-SIRPα途径的阻断。此外，还详细阐述了使用M1巨噬细胞，巨噬细胞来源的外来体和巨噬细胞膜包被的纳米颗粒进行药物递送的最新进展。总体，

更新日期：2020-10-07

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南